Gilde Healthcare
Arthur Franken joined Gilde in 2001. He is focusing on venture and growth capital investments in the biopharm, medtech, diagnostics and digital health sectors. He led the investments in Breath Therapeutics (acquired by Zambon), Conatus Pharmaceuticals (IPO on NASDAQ), FlowCardia (acquired by C. R. Bard), Levicept, Moximed, MTM Laboratories (acquired by Roche), Noema Pharma, ProQR Therapeutics (IPO on NASDAQ) and STAT-Dx (acquired by QIAGEN). He has been involved in numerous investments and divestments including Ablynx (IPO on Euronext, acquired by Sanofi-Aventis), Agendia, Axonics (IPO on NASDAQ), Calypso Biotech, Eargo (IPO on NASDAQ), uniQure (IPO on NASDAQ), BG Medicine (IPO on NASDAQ), CVRx, FIRE1 and Pieris (IPO on NASDAQ).
He represents Gilde on the boards of Calypso, Levicept, Moximed and Noema Pharma and served as a board member for Breath Therapeutics, FlowCardia, MTM Laboratories, ProQR Therapeutics and STAT-Dx until the trade sales or IPO.
Prior to joining Gilde he was active in cardiovascular research at the Leiden/Amsterdam Center for Drug Research and TNO. He holds a master’s degree in Biopharmaceutical Sciences from Leiden University, the Netherlands. He is a Dutch national.
This person is not in any offices
Gilde Healthcare
2 followers
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. Their lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Netherlands, Belgium, and Germany.